期刊文献+

霉酚酸酯治疗狼疮肾炎肾病综合征的疗效观察 被引量:1

Efficacy of mycophenolate mofetil therapy in pateints with lupus nephritis
下载PDF
导出
摘要 目的 回顾性分析 11例糖皮质激素治疗及 /或环磷酰胺治疗无效 ,或因严重副作用无法治疗的狼疮肾炎肾病综合征患者应用霉酚酸酯 (MMF)联合小剂量激素治疗效果。方法 病理检查证实为狼疮肾炎Ⅳ型患者 11例 ,应用糖皮质激素及环磷酰胺治疗受到限制 ,有中~重度狼疮活动依据 ,改用MMF (1 0~ 2 0 g/d)联合小剂量糖皮质激素治疗 6个月以上 [平均 (8 3± 1 5 )个月 ],同期与继续应用泼尼松及 /或环磷酰胺治疗的狼疮肾炎Ⅳ型患者 8例比较 ,观察尿蛋白、狼疮活动指数及肾功能。结果 经过MMF治疗后 ,尿蛋白由治疗前 (3 9± 0 7)g/d下降到治疗后 (1 4± 0 5 ) g/d ,狼疮活动指数明显下降 (治疗前 13 5± 3 3 ,治疗后 3 8± 1 0 ) ,其中 3例肾功能异常患者肾功能恢复正常 ,与对照组比较尿蛋白、狼疮活动指数恢复差异无显著性。 Objective To investigate the curative efficacy of mycophenolate mofetil therapy in lupus patients with nephrotic syndrome.Methods Eleven cases of biopsy proven active diffuse proliferation lupus nephritis to whom previous oral prednisone and/or intravenous cyclophosphamide treatment had been proven ineffective or who had a refractory course and a bad adverse effect,were enrolled for this trial.Mycophenolate mofetil (MMF) was given at a dosage of 1 0~ 2 0 g/d for 6~13 mouths and lower dosage of prednisone every day.At the same time 8 controls of biopsy proven active diffuse proliferation lupus nephritis with nephrotic syndrome who received continuous prednisone and/or cyclophosphamide treatment over 6 months served for comparing and observing usinary protein,SLEDAI and renal function.Results The urinary protein count and the University of Toronto SLEDAI in patients with diffuse proliferation lupus nephritis decreased significantly by mycophenolate mofetil therapy [urinary protein count from (3 9±0 7) g/d to (1 4±0 5) g/d,the index of illness severity of lupus from 13 5±3 3 to 3 8±1 0 respectively].Conclusion The treatment of mycophenolate mofetil plus small dose glucocorticoids can effectively inhibit the lupus activity of lupus nephritis patients.
出处 《中国药物与临床》 CAS 2003年第1期23-26,共4页 Chinese Remedies & Clinics
关键词 霉酚酸酯 治疗 狼疮肾炎 肾病综合征 疗效观察 Lupus nephritis Immunosuppresant Mycophenolate mofetil
  • 相关文献

参考文献16

  • 1[1]Austin HA,Klippel JH.Therapy of lupus nephritis:controlled trial of prednisone and cytotoxic drugs.New Engl J Med,1986,314(10):614-619.
  • 2[2]Valeri A,Radhakrishnan J,Eses D,et al.Intravenous pulse cyclophosphamide treatment of severe lupus nephritis:a prospective five-year study.Clin Nephrol,1994,42(2):71-78.
  • 3唐政,沈克勤,姚小丹,胡伟新,俞雨生,王庆文,刘志红,陈惠萍,季大玺,黎磊石.间断环磷酰胺冲击治疗重症狼疮性肾炎的远期预后[J].肾脏病与透析肾移植杂志,1997,6(1):16-19. 被引量:20
  • 4[4]Briggs WA,Choi MJ,Scheel PJ.Successful mycophenolate mofetil treatment of glomerular disease.Am J Kidney Dis,31(2):213-217.
  • 5胡伟新,刘志红,陈惠萍,唐政,黎磊石.霉酚酸酯治疗顽固性Ⅳ型狼疮性肾炎[J].肾脏病与透析肾移植杂志,1998,7(6):511-515. 被引量:98
  • 6[6]Austin Ⅲ HA,Muenz LR,Joyce KM,et al.Diffuse proliferative lupus nephritis:identification of specific pathologic feature affecting renal outcome.Kidney Int,1984,25(4):689-695.
  • 7[7]Bombardier C,Gladman DD,Vrowitz MB,et al.Derivation of the SLEDAI:a disease activity index for lupus nephritis patients.Arthritis Rheum,1992,35(6):630-640.
  • 8[8]Jonsson CA,Svensson L,Carlsten H.Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.Clin Exp Immunol,1999,116(3):534-541.
  • 9[9]Yu CC,Yang CW,Wu MS,et al.Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.J Lab Clin Med,2001,138(1):69-77.
  • 10[10]Dooley MA,Hogan S,Jennette CJ,et al.Cyclophosphamide therapy for lupus nephritis:poor renal survival in black Americans.Kidney Int,1997,30(6):872-876.

二级参考文献16

共引文献205

同被引文献21

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部